MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents
Método para el tratamiento de cáncer pulmonar.Info
- Publication number
- MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
- Authority
- MX
- Mexico
- Prior art keywords
- fra
- patient
- lung cancer
- level
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G01N33/575—
-
- G01N33/5752—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013390A true MX2017013390A (es) | 2018-06-13 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013390A MX2017013390A (es) | 2015-04-17 | 2016-04-14 | Método para el tratamiento de cáncer pulmonar. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180125970A1 (enExample) |
| EP (1) | EP3283886B1 (enExample) |
| JP (1) | JP2018516244A (enExample) |
| KR (1) | KR20170137848A (enExample) |
| CN (1) | CN107624071A (enExample) |
| AU (1) | AU2016248222A1 (enExample) |
| BR (1) | BR112017022320A2 (enExample) |
| CA (1) | CA2983126A1 (enExample) |
| IL (1) | IL255079A0 (enExample) |
| MX (1) | MX2017013390A (enExample) |
| RU (1) | RU2718780C9 (enExample) |
| SG (1) | SG11201708546UA (enExample) |
| WO (1) | WO2016168440A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| JPWO2015186823A1 (ja) * | 2014-06-06 | 2017-04-20 | 協和発酵キリン株式会社 | Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬 |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| EA202092125A1 (ru) | 2018-03-13 | 2020-12-15 | Фейнз Терапьютикс, Инк. | Антитела против рецептора фолата 1 и их применения |
| KR20210022065A (ko) * | 2018-06-18 | 2021-03-02 | 메디뮨 리미티드 | 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합 |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| KR20240162086A (ko) * | 2022-03-11 | 2024-11-14 | 아스트라제네카 아베 | 항-FRα 항체-약물 접합체 치료법에 대한 점수 산정 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4805848B2 (ja) | 2004-02-12 | 2011-11-02 | モルフォテック、インク． | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
| US20060239910A1 (en) * | 2005-04-22 | 2006-10-26 | Morphotek Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| WO2012061759A2 (en) | 2010-11-05 | 2012-05-10 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| TR201802838T4 (tr) | 2011-07-15 | 2018-03-21 | Eisai R&D Man Co Ltd | Anti-folat reseptör alfa antikorlar ve bunların kullanımı. |
-
2016
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 BR BR112017022320-1A patent/BR112017022320A2/en not_active Application Discontinuation
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017136863A (ru) | 2019-05-17 |
| JP2018516244A (ja) | 2018-06-21 |
| SG11201708546UA (en) | 2017-11-29 |
| BR112017022320A2 (en) | 2018-07-24 |
| RU2017136863A3 (enExample) | 2019-08-21 |
| AU2016248222A1 (en) | 2017-11-09 |
| WO2016168440A1 (en) | 2016-10-20 |
| EP3283886A1 (en) | 2018-02-21 |
| IL255079A0 (en) | 2017-12-31 |
| US20180125970A1 (en) | 2018-05-10 |
| CA2983126A1 (en) | 2016-10-20 |
| KR20170137848A (ko) | 2017-12-13 |
| RU2718780C2 (ru) | 2020-04-14 |
| CN107624071A (zh) | 2018-01-23 |
| EP3283886B1 (en) | 2020-01-15 |
| RU2718780C9 (ru) | 2020-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2023010805A (es) | Metodos terapeuticos y de diagnostico para el cancer. | |
| MX2021009682A (es) | Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
| MX2018005087A (es) | Mutaciones puntuales en cáncer resistente a trk y métodos relacionados con las mismas. | |
| MX2019010150A (es) | Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5. | |
| ES2721639T3 (es) | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama | |
| BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
| MX2017011486A (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. | |
| MX392774B (es) | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| MX2024001734A (es) | Metodo de modificacion de diferenciacion e inmunidad de macrofagos. | |
| CL2020001936A1 (es) | Métodos para el tratamiento de la atrofía muscular espinal. | |
| BR112019025056A2 (pt) | Inibidores de fgfr2 para o tratamento de colangiocarcinoma | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| MX2025004103A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| ES2530732T3 (es) | Procedimientos de diagnóstico para el cáncer de pulmón | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| CY1124881T1 (el) | Στρωματωση γονοτυπου στην θεραπεια και προληψη του διαβητη | |
| ES2571111T3 (es) | Método de diagnóstico para predicción de la respuesta de un paciente a la quimioviroterapia o radioviroterapia | |
| BR112017012287A2 (pt) | uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: EISAI INC. |